Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics Inc. (MYGN) is a leader in molecular diagnostics and precision medicine, developing genetic tests that inform critical healthcare decisions across oncology, hereditary cancer risk assessment, and reproductive health. This news hub provides investors and healthcare professionals with timely updates on the company's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases and third-party analysis covering MYGN's financial results, product innovations, and clinical collaborations. Our curated collection includes updates on diagnostic test approvals, partnership announcements with healthcare systems, and developments in personalized treatment solutions. All content is organized chronologically for efficient tracking of the company's progress in genetic testing technologies.
Key areas of focus include updates to Myriad's hereditary cancer screening panels, advancements in tumor profiling accuracy, and expansions in pharmacogenomic testing capabilities. The page also tracks regulatory submissions and peer-reviewed study publications validating the company's diagnostic approaches.
Bookmark this page for streamlined access to Myriad Genetics' latest developments in DNA-based health solutions. Check regularly for updates on how MYGN continues shaping precision medicine landscape through innovative diagnostic technologies and evidence-based clinical tools.
Myriad Genetics, Inc. (NASDAQ: MYGN) announced that it will hold its first quarter earnings conference call on May 3, 2023, at 4:30 p.m. ET, following the release of its quarterly earnings after market close. The call will cover the company's performance for the period ending March 31, 2023, along with a financial overview and business update. Domestic callers can join by dialing 1-800-582-4086, while international participants can call 1-212-231-2905. A live webcast will be available at Myriad's official website, with a replay accessible for seven days post-call.
Myriad Genetics specializes in genetic testing and precision medicine, providing tests to assess disease risk and guide treatment decisions, ultimately aiming to enhance patient care and reduce healthcare costs.
Myriad Genetics and Intermountain Precision Genomics have received certification from the New York State Department of Health to offer solid tumor testing in all 50 U.S. states. This certification follows a site inspection and represents a significant advancement in precision medicine, enhancing access to genetic testing for cancer patients. The Precise™ Tumor test, also known as TheraMap®, analyzes tumor DNA to identify gene mutations influencing cancer. This certification paves the way for Intermountain and Myriad to provide their Precise Oncology Solutions suite to a larger patient base. Previously, Myriad was certified for other cancer tests, and this certification marks a noteworthy expansion in their service offerings.
Myriad Genetics and SimonMed Imaging announced a partnership to launch a new hereditary cancer assessment program, set to roll out in May 2023. This program combines genetic risk assessment using Myriad's MyRisk and RiskScore tools with diagnostic imaging to enhance patient care. The initiative aims to offer affordable access to genetic testing, helping identify high-risk patients and enabling early diagnosis, which is crucial for effective treatment. The program will be operational in all 86 of SimonMed’s women's imaging sites by year-end. The collaboration underscores the importance of early screening for women at risk of breast cancer, aligning with recent clinical guidelines.
Myriad's commitment to health equity and innovation is emphasized, aiming to improve screening and treatment for younger patients at elevated risk.
FAQ
What is the current stock price of Myriad Genetics (MYGN)?
What is the market cap of Myriad Genetics (MYGN)?
